An interventional study of Milk protein (food grade protein) and Fee amino acids (food grade amino acids) in Intestinal Malabsorption, Critical Illness and Protein Malnutrition, sponsored by Maastricht University Medical Center. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-10.
Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Basic science
In the current study, we willquantitate the difference in digestion and absorption kinetics of dietary whole protein versus free amino acids in vivo in critically ill patients admitted to the intensive care unit suffering from malabsorption. 16 adult, mechanically ventilated ICU patients with clinical signs of malabsorption (faecal weight >350 g/day) will be included. All patients will receive a primed continuous intravenous infusion of L-[ring2H5]-phenylalanine and L-[3,5-2H2]-Tyrosine for the duration of the study period. After reaching an isotopic steady state (1.5 hours), patients will receive either [1-13C]- phenylalanine labelled milk protein or free amino acids with an identical constitution and [1-13C]-phenylalanine.
Main study endpoint will be the splanchnic extraction of phenylalanine, calculated from systemic [1-13C]- and L-[ring2H5]-phenylalanine enrichment.
Background of the study:
The importance of the provision of sufficient protein in critical illness is increasingly recognized. Protein malabsorption seems to be an underestimated but substantial problem in critically ill patients, limiting the amount of this important nutrient that actually becomes available within the systemic circulation. Among several contributors to malabsorption in critical illness, exocrine pancreatic insufficiency has recently emerged as a regularly occurring phenomenon during critical illness. Pancreatic insufficiency could lead to reduced digestion and subsequent uptake of enteral provided proteins. A proposed solution to this problem could be the use of elementary feeds containing free amino acids instead of whole protein. Due to the lack of easy applicable and reproducible tests for protein malabsorption the true efficacy of these feeds is still unknown. We hypothesize that enteral nutrition containing free amino acids leads to higher systemic levels of amino acids and will therefore increase the amount of dietary amino acids available for protein synthesis.
Objective of the study:
To quantitate the difference in digestion and absorption kinetics of dietary whole protein versus free amino acids in vivo in patients admitted to the ICU suffering from malabsorption.
Study design:
Randomized, single-blind controlled, single-centre, intervention study.
Study population:
16 adult, mechanically ventilated ICU patients with clinical signs of malabsorption (faecal weight >350 g/day).
Intervention:
Normal enteral nutrition will be ceased 8 hours before the start of study participation. All patients will receive a primed continuous intravenous infusion of L-[ring2H5]-phenylalanine and L-[3,5-2H2]-Tyrosine for the duration of the study period. After reaching an isotopic steady state (1.5 hours), patients will receive either [1-13C]- phenylalanine labelled milk protein or free amino acids with an identical constitution and [1-13C]-phenylalanine.
Primary study parameters/outcome of the study:
Main study endpoint will be the splanchnic extraction of phenylalanine, calculated from systemic [1-13C]- and L-[ring2H5]-phenylalanine enrichment.
Secundary study parameters/outcome of the study:
Secondary endpoints include the impact of enteral nutrition on whole body protein balance, glucose and insulin concentrations and faecal energy and protein loss as a measure of malabsorption.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
Total study participation will take 16 hours, including 8 hours of fasting. Arterial blood samples will be collected regularly, with 50 ml of blood being sampled in total, amounting to a maximum of 1.0% of total circulating volume. All infusions, as well as blood sample collection, will be performed through indwelling catheters necessary for normal ICU treatment, meaning no lines or nasogastric tubes will have to be placed for the purposes of the study. Both isotopically labelled protein and free amino acids have been proven safe for use in humans and carry no harmful risks for the study participant. Changes in protein digestion, absorption and metabolism are specific to critical illness and their impact on the clinical condition and recovery of patients is severe. Investigating new strategies to modulate these effects are therefore essential, but require experimental studies in a vulnerable population. The risks in the present study are minimal whereas the results could help improve nutritional management in the intensive care.
54 studies on the registry are indexed under Malabsorption Syndromes; 12 are open to participants now.
This study's enrollment of 16 is below the median of 38 across 44 interventional studies indexed under Malabsorption Syndromes.
Browse Malabsorption Syndromes studies →Maastricht University Medical Center is the lead sponsor of 853 studies on the registry; 114 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive 20 grams of Intrinsically labelled milk protein.
Dietary Supplement: Milk protein (food grade protein)
Patients receive 20 grams of free amino acids equivalent to the milk protein labelled with 13C-Phenylalanine
Dietary Supplement: Fee amino acids (food grade amino acids)
Subjects will receive an enteral nutritional formula containing 20 grams intrinsically labeled (1-\[13C\]-phenylalanine) milk protein
Also known as: Protein
Nutritional formula containing 20 grams of a free amino acid mixture equivalent in composition to the milk protein with 1-\[13C\]-labeled phenylalanine
Also known as: Amino Acids
systemic availability of diet-derived amino acids
The main study endpoint in this study is the systemic availability of enteral administered protein-bound or free amino acid nutrition, including the rate of appearance (Ra) of dietary derived phenylalanine. Modified Steele's equations will be applied to plasma enrichments of L-\[ring-2H5\]-phenylalanine, L-\[1-13C\]-phenylalanine enrichment, L-\[ring-2H4\]-tyrosine and L-\[3,5-2H2\]-tyrosine.
Time frame: 8 hours
Total plasma amino acids (AAmax [μmol/L])
Total plasma amino acids (AAmax \[μmol/L\])
Time frame: 8 hours
Plasma glucose (glucosemax [mmol/L])
Plasma glucose (glucosemax \[mmol/L\])
Time frame: 8 hours
Plasma insulin (insulinmax [mU/L])
Plasma insulin (insulinmax \[mU/L\])
Time frame: 8 hours
Intestinal absorption capacity (energy provided - fecal energy loss x 100%)
Intestinal absorption capacity (energy provided - fecal energy loss x 100%)
Time frame: 2 x 24 hours
Fecal elastase (µg elastase / g feces)
Fecal elastase (µg elastase / g feces)
Time frame: 2 x 24 hours
Fecal presence of L-[1-13C]-phenylalanine
Fecal presence of L-\[1-13C\]-phenylalanine
Time frame: 2x 12 hours
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amino Acids
Maastricht University Medical Center →